CAH Stock Analysis — Cardinal Health
Sector: Healthcare Distribution
AI Verdict
Cardinal Health trades at 19.2x next year's earnings with 90.9% EPS growth expected—cheap for the growth on offer if its distribution scale keeps competitors at bay, but the high RSI means short-term buyers risk getting caught in a pullback.
Competitive Moat
Cardinal Health operates one of the largest pharmaceutical and medical supply distribution networks in the U.S., giving it scale advantages and deep relationships with hospitals and pharmacies. Its logistics infrastructure and long-term contracts create high switching costs for customers.
Summary
A 90.9% jump in expected earnings has pushed Cardinal Health's forward P/E down to 19.2x, drawing attention after a 45.37% one-year return.
Where It Stands
Cardinal Health is up 45.37% over the past year, trades at 19.2x forward earnings (below the 22x healthcare median), but its RSI of 68.8 signals elevated pullback risk.
Key Metrics
- RSI: 68.8 — Near Overbought
- Trailing P/E: 36.6x
- Forward P/E: 19.2x
- PEG Ratio: 0.40
- Earnings Growth: +0.9%
- Revenue Growth: +0.1%
- Market Cap: $56.0B
- Dividend Yield: 0.01%
- 1-Year Return: 45.37%
- 52-Week High: $243.21
- 52-Week Low: $137.75
Analyst Consensus
20 Buy · 3 Hold · 0 Sell (23 analysts)
Bull Case
With forward EPS growth forecast at 90.9% and a forward P/E of 19.2x, you're paying a below-sector multiple for explosive earnings momentum.
Bear Case
The RSI of 68.8 is near overbought territory, so a pullback to neutral RSI could erase a chunk of the recent 45.37% gain even if fundamentals hold.
Catalyst to Watch
Watch the next quarterly earnings for confirmation that EPS growth is tracking toward the 90.9% analyst estimate—any miss could trigger a sharp re-rating.